HTMC0435 and Temozolomide in Treating Patients With Small Cell Lung Cancer

A Phase 1b/2, Dose-finding and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HTMC0435 With Temozolomide in Patients With Small Cell Lung Cancer

The Phase 1b part of this clinical trial is to investigate the safety and pharmacokinetic (PK) characteristics of HTMC0435 tablets combined with temozolomide in patients with various advanced solid tumors (recurrent small cell lung cancer is preferred). The Phase 2 part of the study is a multi-center, open-label, single-arm trial to investigate the preliminary efficacy of HTMC0435 and temozolomide in patients with recurrent small cell lung cancer (SCLC) at the recommended phase 2 dose.

Study Overview

• Status: Recruiting
• Conditions: Recurrent Extensive Stage Small Cell Lung Carcinoma
• Intervention / Treatment: Drug: HTMC0435; Drug: Temozolomide

• Study Type: Interventional
• Enrollment (Estimated): 64
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Jun Li; Phone Number: +86-21-64311017; Email: clinical_trial@hllife.com.cn

Study Locations

• China
  • Hangzhou, China
    • Recruiting
    • Zhejiang Cancer Hospital
  • Nanjing, China
    • Recruiting
    • Jiangsu Province Hospital of Chinese Medicine
  • Zhengzhou, China
    • Recruiting
    • Henan Cancer Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Male or female, age ≥18 and <75 years old
2. Patients with histologically or cytologically confirmed recurrent or progressive extensive-stage SCLC, who have previously received at least first-line and no more than second-line treatments (HRR mutations are preferred)
3. [Only applicable to phase II part] At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
4. Eastern Cooperative Oncology Group (ECOG) performance status of 0~1
5. Expected survival period ≥3 months
6. Prior to the enrollment, no serious hematopoietic abnormality, and generally normal function of heart, lung, liver and kidney
7. Understand and sign the informed consent form (ICF) voluntarily. Be willing and able to complete routine visits, treatment plans, laboratory examinations and other procedures.

Exclusion Criteria:

1. Prior treatment with any poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor
2. Prior temozolomide treatment interruption caused by toxicity
3. Received treatment with chemotherapy, radiation, biotherapy, endocrine therapy, immunotherapy, or other anti-tumor therapy ≤4 weeks prior to the first dose of HTMC0435
4. Any unrecovered AE of prior therapy ≥CTCAE 5.0 Grade 1 (except for toxicity that the investigators judged to have no safety risks, such as alopecia)
5. Currently suffering from interstitial lung disease ≥CTCAE Grade 2
6. Major surgery (excluding needle biopsy) within 4 weeks before the first dose of HTMC0435
7. Past surgical history or severe gastrointestinal diseases that the investigator believes may affect the absorption, distribution or metabolism of the study drug, such as dysphagia, active gastric ulcer, ulcerative colitis, Crohn's disease, ileus, etc.
8. History of severe cardiovascular and cerebrovascular diseases
9. Received CYP3A4 potent inhibitors or inducers within 7 days before the first dose of HTMC0435 or need to use these medications during the study
10. Symptomatic brain metastases or meningeal metastases. Patients with these metastases who have received related treatment need to meet the following conditions before they can be enrolled: no radiographic evidence of progression ≥ 4 weeks after the end of treatment; completion of treatment ≥ 28 days before the first dose; no need for systemic corticosteroids treatment (>10 mg/day prednisone or equivalent dose) within 14 days before the first dose of HTMC0435
11. Active infectious diseases which need systemic anti-infection treatment
12. Hepatitis B surface antigen (HBsAg) positive with hepatitis B virus (HBV) -DNA >1000 copies/mL or >200 IU/mL; hepatitis C virus antibody (HCV-Ab) positive
13. Human immunodeficiency virus antibody (HIV-Ab) positive
14. Previous or current diagnosis of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)
15. Women who are pregnant or breastfeeding; women/men who are planning to have a child; women/men who refuse to use medically approved contraceptive measures for contraception during the study treatment and within 6 months after the end of the study
16. Serious psychological or mental abnormalities that may affect compliance of patients in this study
17. Current alcohol or drug abusers
18. Judgment by the investigator that the patient is not suitable for this study due to other conditions

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Phase 1b; Escalating doses of HTMC0435 and Temozolomide	Drug: HTMC0435; Oral administration.; Drug: Temozolomide; Oral administration.
Experimental: Phase 2; Recommended phase 2 dose (RP2D) of HTMC0435 and Temozolomide	Drug: HTMC0435; Oral administration.; Drug: Temozolomide; Oral administration.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Dose-limiting toxicities (DLT) of HTMC0435 combined with Temozolomide	Cycle 1 Day 1 to Cycle 1 Day 21
Adverse events (AE) of HTMC0435 combined with Temozolomide	Through study completion, an average of 6 months
Maximum tolerable dose (MTD) and RP2D of HTMC0435 combined with Temozolomide	Through study completion, an average of 6 months

Secondary Outcome Measures

Outcome Measure	Time Frame
Pharmacokinetic measures - the area under the concentration-time curve from dosing (time 0) to time infinity (AUC 0-inf)	Cycle 1 Day 1 to Cycle 1 Day 9
Pharmacokinetic measures - the area under the concentration-time curve from dosing (time 0) to time t (AUC 0-t)	Cycle 1 Day 1 to Cycle 1 Day 9
Pharmacokinetic measures - apparent clearance rate (CLz/F)	Cycle 1 Day 1 to Cycle 1 Day 9
Pharmacokinetic measures - maximum plasma concentrations (Cmax)	Cycle 1 Day 1 to Cycle 1 Day 9
Pharmacokinetic measures - time to reach Cmax (Tmax)	Cycle 1 Day 1 to Cycle 1 Day 9
Pharmacokinetic measures - trough concentrations at steady state (Css, min)	Cycle 1 Day 1 to Cycle 1 Day 9
Pharmacokinetic measures - peak concentrations at steady state (Css, max)	Cycle 1 Day 1 to Cycle 1 Day 9
Pharmacokinetic measures - accumulation ratio (Rac)	Cycle 1 Day 1 to Cycle 1 Day 9
Pharmacokinetic measures - terminal plasma half-life (T1/2)	Cycle 1 Day 1 to Cycle 1 Day 9
Pharmacokinetic measures - apparent volume of distribution during terminal phase (Vz/F)	Cycle 1 Day 1 to Cycle 1 Day 9
Objective response rate (ORR) by RECIST v1.1	Through study completion, an average of 6 months
Disease control rate (DCR) by RECIST v1.1	Through study completion, an average of 6 months
Progression-free survival (PFS) by RECIST v1.1	Through study completion, an average of 6 months
Duration of response (DOR) by RECIST v1.1	Through study completion, an average of 6 months
Overall survival (OS) by RECIST v1.1	Through study completion, an average of 6 months

Other Outcome Measures

Outcome Measure	Time Frame
Changes in neuron-specific enolase (NSE) level from baseline	Through study completion, an average of 6 months
Changes in pro-gastrin-releasing peptide (PROGRP) level from baseline	Through study completion, an average of 6 months

Collaborators and Investigators

• Sponsor: Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
• Investigators: Principal Investigator: Yun Fan, MD, Zhejiang Cancer Hospital

Study record dates

Study Major Dates

• Study Start (Actual): February 3, 2023
• Primary Completion (Estimated): August 1, 2024
• Study Completion (Estimated): October 1, 2024

Study Registration Dates

• First Submitted: January 10, 2023
• First Submitted That Met QC Criteria: February 5, 2023
• First Posted (Actual): February 15, 2023

Study Record Updates

• Last Update Posted (Actual): September 28, 2023
• Last Update Submitted That Met QC Criteria: September 26, 2023
• Last Verified: January 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Neoplasms; Lung Diseases; Neoplasms by Site; Respiratory Tract Neoplasms; Thoracic Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Small Cell Lung Carcinoma; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Alkylating Agents; Temozolomide
• Other Study ID Numbers: HLND-01-TMZ-Ib/II-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No